HIV-1 from infected subjects has been characterized in order to provide a more accurate view of the strains that are currently found in a given region. In this report, we focused on characterizing the pol gene diversity obtained from newly diagnosed patients in Santos metropolitan area, Brazil. This region is composed of nine cities and an international port. Analysis of the 33 samples revealed that 22 strains belonged to subtype B, 4 to subtype F, and 2 to subtype C; 5 strains were B/F recombinants. Our results demonstrated that 18.2% of samples were primary antiretroviral resistance genotypic mutations, with high-level resistance to reverse transcriptase inhibitors in both subtypes B and F and in recombinant forms B/F. Our data revealed that the primary antiretroviral resistance genotypic mutations should be carefully investigated in developing countries with widespread access to antiretrovirals, such as Brazil.
Introduction: Bickerstaff encephalitis is a rare disease and considered a spectrum of the Guillain Barré syndrome. We present a case report of subacute onset of gait impairment, impaired consciousness, ophthalmoplegia, respiratory dysfunction and severe dysautonomia with atypical and diffuse brainstem and diencephalic white matter abnormalities, a positive seric GQ1B and neurological recovery after two cycles of immunoglobulin and plasmapheresis. The aim is to describe an atypical case of Bickerstaff encephalitis. Case report: A 30-year-old man was admitted with a ten days history of vertigo, dysphagia, bilateral ptosis and tetraparesis with brachial predominance. His examination showed appendicular ataxia, tetraparesis, ophthalmoplegia and ptosis. Due to the clinical presentation, we started treatment with immunoglobulin but he evolved with need of mechanical ventilation and had two cardiac arrests due to severe dysautonomia. His lumbar puncture showed no albuminocytologic dissociation. His magnetic resonance imaging showed nonspecific foci signal hyperintensities on FLAIR (Fluid-Attenuated Inversion Recovery) in cerebellum, hippocampus and globus pallidus. His serum GQ1B testing was positive, confirming the initial clinical hypothesis of Bickerstaff encephalitis. He was submitted to plasmapheresis and a second cycle of immunoglobulin, with complete clinical recovery six months after. Conclusion: We described a case of atypical Bickerstaff encephalitis, highlighting the importance of recognizing atypical clinical patterns for an appropriate treatment.
Case report: A 62-year-old patient was transferred from another hospital with complaints of subacute torpor and fever two months after an allogeneic bone marrow transplant. He had the diagnosis of chronic myelomonocytic leukemia type 2 four years before the beginning of the neurological symptoms. The disease remained stable for two years after the diagnosis, but progressed and he was submitted to a bone marrow transplant. The complications during the procedure were a febrile neutropenia, that resolved with a cycle of antibiotics, and a reactivation of cytomegalovirus (CMV) infection (he had a high risk to reactivation due to the status of antibodies of the donator, that was negative, and he had positive antibodies). He remained stable and was discharged from the hospital 30 days after the transplant. Two months after the transplant, the fever and torpor began, and he went to the emergency department in his hometown. There, he was diagnosed with a positive coronavirus disease 2019 (COVID-19) infection and reactivation of cytomegalovirus, with prescription of endovenous ganciclovir, without clinical improvement. His clinical symptoms evolved to loss of balance and progressive torpor, and was transferred to our hospital for clinical evaluation. In the initial examination, he was febrile, torporous, he was not collaborative to the neurological examination due to the level of consciousness. He was hypotonic and had withdrawal from a painful stimulus on four limbs. His tendinous reflexes were hyperactive and symmetrical. Due to his level of consciousness, the cerebellar maneuvers were not testable. He was then submitted to orotracheal intubation due to neurological deterioration. In his complementary investigation, the serum polymerase chain reaction (PCR) for CMV was already negative and his PCR for COVID-19 was also negative. The electroencephalogram showed slow generalized periodic discharges. His computerized tomography showed no abnormalities, so he was submitted to a lumbar puncture that showed 8 cells, with 97% lymphocytes, 74 mg/dL of protein, 26 mg/dL of glucose with no neoplasic cells and a positive PCR for Toxoplasma gondii. The PCR for mycobacterium tuberculosis, cryptococcosis, and viruses were negative. After the results, we started sulfadiazine and pyrimethamine and he was submitted to a magnetic resonance imaging that showed multiple nodular foci of hypersignal in T2/FLAIR (T2-weighted-Fluid-Attenuated Inversion Recovery) and diffusion abnormalities on the cortical surface of the cerebellar hemispheres, thalamus, basal ganglia and subcortical white matter of the cerebral hemispheres, being more evident in the cerebellum and basal ganglia. Besides the atypical radiological findings for neurotoxoplasmosis, his serologic testing on the serum showed an positive immunoglobulin M and immunoglobulin G for Toxoplasma gondii. He had no clinical improvement with the antibiotics, and so, ten days after he was submitted to a new magnetic resonance imaging showing increase in the size and number of multiple small focal lesions with hypersignal on T2/FLAIR in the brain parenchyma, highlighting confluent lesions in the basal ganglia and focal lesions in the cerebellar hemispheres, which show contrast uptake, as well as in the thalamus and midbrain. His neurological symptoms evolved and he showed a minimally conscious state, with spasticity in the four limbs. He was submitted to a new lumbar puncture that showed 1 cell, 78 mg/dL of protein and 50 mg/dl of glucose, an improvement, despite clinical and radiological worsening. Because of the clinical worsening, he was submitted to a brain biopsy. His cerebral biopsy was negative for neoplasic infiltration of the cerebral nervous system, viral infections, cryptococcus and toxoplasmosis. It showed an interstitial CD3 lymphocytic inflammation with vasculitis and frequent macrophages, very rare CD20 lymphocytes and p24 and SV-40 negative. His neuropathological criteria were compatible with CLIPPERS (chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids). The patient was submitted to five days of metilprednisolone and with oral prednisone after, with slow clinical improvement, but probably due to the lack of systemic clinical status of the patient and delayed diagnosis because of the atypical presentation, the patient died of pneumonia.
Introduction: The investigation of hemorrhagic demyelinating cerebral lesions is challenging with diverse etiologies. We report a case of varicella zoster virus (VZV) infection with prominent hemorrhagic demyelinating component and systemic thrombosis. Objectives: Describe a case of hemorrhagic demyelinating lesions and systemic thrombosis secondary to varicella zoster central nervous system infection. Case report: A 45-year-old man presented with a one-week history of left leg strength loss associated with pyramidal liberation on the left side. Brain MRI showed two expansive hemorrhagic lesions, in the frontoparietal lobe and in the cingulate gyrus region. There were T2/FLAIR hypersignal in the subcortical area of both cerebral hemispheres and in the cervical cord, suggestive of demyelination. His arterial magnetic resonance imaging with vessel wall imaging showed focal tapering on the pial branches of the middle cerebral artery, but his digital angiography showed no abnormalities. The lumbar puncture had 8 cells, (lymphocyte predominance), 52 proteins/ dL, and 53 mg/dL of glucose. In two days, he developed a left side hemiplegia associated with seizures and pulmonary thromboembolism, demanding lung mechanical thrombectomy and anticoagulation. He had a positive lupus anticoagulant and a positive VZV IgG in the cerebrospinal fluid associated with positive oligoclonal bands. He received intravenous acyclovir with complete resolution of the symptoms. Conclusion: The clinical manifestations of VZV infection are wide, and we should suspect of this infection in patients with central nervous system demyelinating lesions, even without other skin lesions.
Introduction: Mantle cell lymphoma (MCL) is a subtype of uncommon nonHodgkin lymphoma. The involvement of the central nervous system (CNS) is uncommon in the course of the disease. Objective: To report a case of recurrence of MCL in the CNS as the first manifestation, after chemotherapy and bone marrow transplantation. Case report: Male patient, 49 years old, with no previous comorbidities diagnosed with stage IV MCL (bone marrow), submitted to chemotherapy and autologous transplantation. After two years, he sought out the neurology clinic with a complaint of blurred vision. Neurological examination: without motor deficit; bilateral partial ptosis, bilateral divergent strabismus, tongue shift to the right. CSF with 230 leukocytes/mm³, 70% of lymphocytes, glucose of 71 mg /dl and protein of 85 mg /dl; Skull MRI demonstrated bilateral and symmetrical enhancement of segments of the cisterns of the optic and oculomotor nerves; Trigeminal, facial, vestibulocochlear and glossopharyngeal, vagus and accessory nerves more exuberant on the left. CSF immunophenotyping showed CD19, CD5 and Kappa positive monoclonal, compatible with MCL recurrence. Intrathecal and systemic chemotherapy with methotrexate were initiated. Discussion: Risk of recurrence of MCL and infiltration of the CNS is uncommon (3.9 - 5%). The patient did not show any signs of systemic involvement, only the neurological findings, which is atypical since the neurological presentation is more associated with recurrence of MCL with a course of systemic findings. Conclusion:The authors point out that in patients with treated MCL who have neurological manifestations without systemic findings, tumor recurrence should be considered.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.